Jeff Hartness - Bausch Health Commercial Access
| BHC Stock | USD 6.35 0.02 0.31% |
Insider
Jeff Hartness is Commercial Access of Bausch Health Companies
| Phone | 514 744 6792 |
| Web | https://www.bauschhealth.com |
Bausch Health Management Efficiency
The company has Return on Asset of 0.0404 % which means that on every $100 spent on assets, it made $0.0404 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Bettington | Zoetis Inc | 46 | |
| Abbas Hussain | Teva Pharma Industries | 55 | |
| Andrew Weil | Teva Pharma Industries | 52 | |
| David Bayles | Viatris | N/A | |
| Eric Drape | Teva Pharma Industries | 62 | |
| Robert Herrman | PetIQ Inc | 55 | |
| Wafaa Mamilli | Zoetis Inc | 57 | |
| James Meiers | Tilray Inc | 66 | |
| Kare Schultz | Teva Pharma Industries | 63 | |
| Dara Redler | Tilray Inc | N/A | |
| Zvi Glasman | PetIQ Inc | 60 | |
| Robert Coury | Viatris | 63 | |
| Jude Onyia | Neurocrine Biosciences | 59 | |
| J McFarland | Zoetis Inc | 61 | |
| Robert Kelly | Zoetis Inc | 48 | |
| Tamara Rogers | Haleon plc | 54 | |
| Sanjeev Narula | Viatris | 63 | |
| Marvin White | Emergent Biosolutions | 58 | |
| Sanjeev Sethi | Viatris | 57 | |
| Steven Gillis | Takeda Pharmaceutical Co | 67 | |
| Eiry MD | Neurocrine Biosciences | 59 | |
Management Performance
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0404 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| D Hale, Independent Director | ||
| Jeff Hartness, Commercial Access | ||
| John Barresi, Controller, VP | ||
| Sarah Kavanagh, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Tage MD, Chief RD | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Robert Butz, VP Affairs | ||
| Paul Herendeen, Chief Financial Officer, Executive Vice President | ||
| Brett Icahn, Independent Director | ||
| Richard Schutter, Independent Director | ||
| Seana Carson, Executive Counsel | ||
| Josh Coyle, Senior Salix | ||
| Amy Wechsler, Independent Director | ||
| Graham Jackson, Senior Officer | ||
| Sam Will, Senior Vice President - Finance, Chief Accounting Officer, Controller | ||
| Robert Power, Independent Director | ||
| Thomas Vadaketh, Ex CFO | ||
| Argeris Karabelas, Independent Director | ||
| Kathleen Fitzpatrick, Senior Officer | ||
| Joseph Gordon, President and Co-Head Bausch + Lomb/International | ||
| Jiny MBA, Senior Medical | ||
| Christina Ackermann, Executive Vice President, General Counsel and Head of Commercial Operations | ||
| Thomas Ross, Lead Independent Director | ||
| Donald Pearl, Senior Dermatologics | ||
| Andrew Eschenbach, Independent Director | ||
| Mirza Dautbegovic, Senior COO | ||
| Joseph Papa, Chairman of the Board, Chief Executive Officer | ||
| John Paulson, Independent Director | ||
| Steven Miller, Independent Director | ||
| Thomas Appio, Executive Vice President Company Group Chairman, International | ||
| Robert Spurr, President - Salix | ||
| Cees Heiman, Senior Canada | ||
| Russel Robertson, Independent Director |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0404 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 24.62 B | ||||
| Shares Outstanding | 366.8 M | ||||
| Shares Owned By Insiders | 0.93 % | ||||
| Shares Owned By Institutions | 80.04 % | ||||
| Number Of Shares Shorted | 20.51 M | ||||
| Price To Earning | 9.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. Note that the Bausch Health Companies information on this page should be used as a complementary analysis to other Bausch Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Bausch Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.